A phase 1, Multicenter, Open-label, Dose-escalation and expansion, Safety, Pharmacokinetic, Pharmacodynamic, and clinical activity study of orally administered AG-120 in subjects with advanced solid tumors, including glioma, With an IDH1 mutation. Here, IDH1 is linked to glioma.